Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Beck

Obstetrics & Gynecology Gillette, WY Medical Doctor

NPI 1073626339 CMS profile 764174

1402 West 4Th Street, Gillette, WY 82716

Open in the dashboard

General payments

$1,917

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Beck of Gillette, WY is reported in the CMS Open Payments database as having received $1,917 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $309 14
2024 General $155 8
2023 General $150 9
2022 General $499 25
2021 General $501 30
2020 General $133 9
2019 General $170 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Beck
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to David Beck were reported at $309. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year David Beck Obstetrics & Gynecology median Middle half National median
2019 $170 $172 $62–$391 $163
2020 $133 $94 $36–$222 $114
2021 $501 $136 $42–$369 $132
2022 $499 $160 $50–$433 $149
2023 $150 $169 $56–$423 $160
2024 $155 $152 $50–$371 $164
2025 $309 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $591 33 payments
  2. Amgen Inc. $141 10 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $124 8 payments
  4. Novo Nordisk Inc $118 6 payments
  5. Biohaven Pharmaceuticals, Inc. $75 3 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $75 3 payments
  7. Merck Sharp & Dohme Corporation $70 5 payments
  8. Daiichi Sankyo Inc. $68 4 payments
  9. Pfizer Inc. $59 3 payments
  10. Lilly USA, LLC $58 3 payments
  11. Other $537 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,894 105 payments
  2. Education $23 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $239 11 payments
  2. NURTEC ODT $150 6 payments
  3. EVENITY $141 10 payments
  4. VRAYLAR $113 5 payments
  5. Prolia $107 8 payments
  6. TRINTELLIX $85 5 payments
  7. ORILISSA $83 8 payments
  8. QULIPTA $82 5 payments
  9. ORIAHNN $79 7 payments
  10. NEXPLANON $70 5 payments
  11. Other $1,176 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

488

Median for Obstetrics & Gynecology: 65

Drug cost

$36,164

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

16.6%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 11 $9,522
Veozah Fezolinetant Brand 12 $7,476
Myrbetriq Mirabegron Brand 11 $7,403
Estradiol Generic 70 $4,836
Yuvafem Estradiol Brand 15 $1,444
Synthroid Levothyroxine Sodium Brand 15 $864
Oxybutynin Chloride Er Oxybutynin Chloride Brand 17 $675
Omeprazole Generic 28 $633
Ibuprofen Generic 16 $578
Pantoprazole Sodium Generic 21 $453

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$68,237

Of which drugs: $52,744

Medicare patients

96

Average age 70

Services billed

4,141

96 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 49%
Arthritis 40%
Osteoporosis 23%
Ischemic heart disease 20%
Diabetes 16%
COPD 16%
Cancer 14%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 24 1,620 $32,796

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MONOFERRIC
  • Pharmacosmos Therapeutics Inc. $35
$35 — —
Wegovy
  • Novo Nordisk Inc $21
$21 — —
INJECTAFER
  • Daiichi Sankyo Inc. $21
$21 — —
CONTRAVE
  • Currax Pharmaceuticals LLC $17
$17 — —
EVENITY
  • Amgen Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record